CELCCelcuity Inc.
Services-Medical Laboratories
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$172M
- 52% YoY
- Market cap
- $3.4B
- Employees
- 500
- Net debt / EBITDA
- —
- −$182M net debt
- AI in 10-K
- 1.2
- mentions per 10K words
Takeover score 2 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo90% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo1.2 per 10K words · 39th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$3.4B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$328M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$28M | −$39M | −$66M | −$113M | −$172M | 52% |
| Net income | −$30M | −$40M | −$64M | −$112M | −$177M | 58% |
| Operating cash flow | −$20M | −$36M | −$54M | −$83M | −$153M | 84% |
| Capex | $82K | $159K | $98K | $250K | $249K | 0.4% |
| Stock-based comp | $3M | $5M | $5M | $7M | $21M | 206% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Jul 16, 2026 | BAKER BROS. ADVISORS LP | SCHEDULE 13D/A | 30.0% | Passive |
| Mar 24, 2026 | BAKER BROS. ADVISORS LP | SCHEDULE 13D/A | 20.0% | Passive |
| Mar 9, 2026 | Growth Equity Opportunities 18 VGE, LLC | SCHEDULE 13D/A | 4.9% | Passive |
| Jan 16, 2026 | Growth Equity Opportunities 18 VGE, LLC | SCHEDULE 13D/A | 6.3% | Passive |
| Aug 18, 2025 | Growth Equity Opportunities 18 VGE, LLC | SCHEDULE 13D/A | 8.1% | Passive |
| Aug 1, 2025 | BAKER BROS. ADVISORS LP | SCHEDULE 13D | 59.9% | Passive |
| Sep 12, 2022 | Growth Equity Opportunities 18 VGE, LLC | SC 13D/A | 10.0% | Passive |
| May 24, 2022 | Growth Equity Opportunities 18 VGE, LLC | SC 13D | 8.4% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $328M · 17
- Net
- −$328M
Pay vs performance
No pay-versus-performance disclosure yet.